Literature DB >> 12925052

Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan.

W-J Liu1, L-T Lee, M-F Yen, T-H Tung, R Williams, S W Duffy, T H-H Chen.   

Abstract

AIMS: The natural history and treatment efficacy of diabetic retinopathy (DR) play important roles in the evaluation of screening. Therefore, the natural history of DR and rates of transition after treatment (including metabolic control and laser photocoagulation) from no diabetic retinopathy (NDR) to blindness were quantified.
METHODS: We studied a cohort of 795 patients with diabetes mellitus (DM) receiving fundus examination in the ophthalmology out-patient department of one medical centre between 1 January 1990 and 31 December 1992 in Taiwan. Follow-up data until 31 December 1998 were collected by chart review. Two multistate Markov models were proposed to assess the efficacy of the treatment regime in reducing progression to blindness.
RESULTS: The average times spent in states (i) no diabetic retinopathy (NDR), (ii) background diabetic retinopathy (BDR), (iii) preproliferative diabetic retinopathy (PPDR), and (iv) proliferative retinopathy (PDR) were 10.86 years, 8.33 years, 1.67 years, and 2.17 years, respectively. Early detection of PPDR may lead to a 60% reduction in PDR and an 83% reduction in blindness. Simulated results based on these parameters show that an annual screening programme, a biennial screening regime and a 4-yearly screening regime can lead to 54% (95% confidence interval (CI): 44-62%), 51% (95% CI: 41-59%), and 46% (95% CI: 36-54%) reductions in blindness, respectively.
CONCLUSIONS: Assessing the progression of DR following the proliferative pathway in this study suggests that screening for DR is worthwhile and that a 4-year interscreening interval for patients as yet without DR may be justified.

Entities:  

Mesh:

Year:  2003        PMID: 12925052     DOI: 10.1046/j.1464-5491.2003.01019.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

Review 1.  Current state of care for diabetic retinopathy in India.

Authors:  Kim Ramasamy; Rajiv Raman; Manish Tandon
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

2.  Assessing type I error and power of multistate Markov models for panel data-A simulation study.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  Commun Stat Simul Comput       Date:  2016-09-23       Impact factor: 1.118

3.  Using Markov Chains to predict the natural progression of diabetic retinopathy.

Authors:  Priyanka Srikanth
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

4.  Multilocus genetic risk score for diabetic retinopathy in the Han Chinese population of Taiwan.

Authors:  Wen-Ling Liao; Jang-Ming Lin; Wen-Lu Chen; Ming-Chia Hsieh; Chia-Ming Wu; Ya-Wen Chang; Yu-Chuen Huang; Fuu-Jen Tsai
Journal:  Sci Rep       Date:  2018-09-28       Impact factor: 4.379

5.  Causal Relationship between Adiponectin and Diabetic Retinopathy: A Mendelian Randomization Study in an Asian Population.

Authors:  Yu-Chuen Huang; Ya-Wen Chang; Chun-Wen Cheng; Chia-Ming Wu; Wen-Ling Liao; Fuu-Jen Tsai
Journal:  Genes (Basel)       Date:  2020-12-24       Impact factor: 4.096

6.  Early Screening for Diabetic Retinopathy in Newly Diagnosed Type 2 Diabetes and Its Effectiveness in Terms of Morbidity and Clinical Treatment: A Nationwide Population-Based Cohort.

Authors:  Yu-Chien Chung; Ting Xu; Tao-Hsin Tung; Mingchih Chen; Pei-En Chen
Journal:  Front Public Health       Date:  2022-04-26

7.  Risk factors for visual impairment and blindness amongst black adult diabetics receiving treatment at Government healthcare facilities in Mopani District, Limpopo province, South Africa.

Authors:  Raymond G Mabaso; Olalekan A Oduntan
Journal:  Afr J Prim Health Care Fam Med       Date:  2014-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.